Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Cerus Q3 2026 Results: Net Loss of $550K, Loss Widens

For the quarter ended September 30, 2026, Cerus Corporation reported product revenue of $57.7 million, a 9.5% increase over the prior year, and achieved a narrow net loss of $0.6 million. The company significantly reduced its nine-month net loss from $13.5 million in 2025 to $5.2 million in 2026, driven by higher gross profits and lower research and development expenses.

Watch the Cerus Corp earnings callFull call on the ALFA USA YouTube channel
Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue57.752.7
Profit before tax-0.50.1
Net income-0.6-0.0
EPS (diluted, $ a share)$-0.00$-0.00

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+9.5%
Operating margin0.7%
Source

10-Q filed with the SEC, NASDAQ: CERS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Cerus Corp: key numbers

Share price
$1.86Close, Nov 16
Market cap
$376M
Shares outstanding
201.95MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Cerus Corp

All →
4:08 PM ET 8-K
Financial Results

Cerus Financial Results

Cerus Corporation reported Q3 2026 total revenue of $64.0 million, driven by 10% year-over-year growth in product revenue to $57.7 million. The company also announced positive topline Phase 3 results for its INTERCEPT Blood System for red blood cells and generated $3.0 million in operating cash flow during the quarter.

Term
Q3 2026

“Our solid performance in Q3 builds upon a strong first half of 2026 and increases our confidence as we approach year-end. Continued growth from our IFC business, core platelet franchise and international INT 200 rollout strengthens our foundation as we work to establish INTERCEPT as the global standard of care.”

Vivek Jayaraman, Cerus’s president and chief executive officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.